PCED1B

Across TCGA pan-cancer cohorts, PCED1B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCED1B data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PCED1B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCED1B expression acts as an unfavorable survival marker.

HNSC, LSCC, and LUAD are the cancer types where PCED1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.774	1.000	.027	5	view →
LSCC	DFS	Median	II,III,IV	0.379	0.831	.038	2	view →
LUAD	OS	Median	All	0.459	0.982	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PCED1B–HNSC (DFS)

Open the HNSC breakdown →